42 results about "Myosin" patented technology

The invention belongs to the technical field of food processing, and discloses application of muscle protein in a protein product, the protein product and a manufacturing method of the protein product. The protein product comprises the following components in parts by weight: 1-5 parts of recombinant myosin; and 5-9 parts of animal protein or vegetable protein. The recombined muscle protein is creatively adopted to improve the texture and flavor of the plant meat, and experiments prove that the recombined muscle protein (FW protein) can perfectly simulate the texture of a real meat product after being subjected to simple cross-linking treatment, and meanwhile, the recombined muscle protein has the function of a protein-based adhesive. Animal protein in meat products can be completely or partially replaced, dependence on animal husbandry is remarkably reduced, and the sustainable food production requirement is met. In the hot processing (such as extrusion and cooking) process, the recombinant muscle protein can form a stable three-dimensional network structure, so that the product is endowed with good elasticity and slicing property, the problems of loose texture and fragility of the traditional vegetable protein product are solved, the use of additives is reduced, and the production process is simplified.

The present application relates to the technical field of health care products, in particular to a pelvic floor muscle repairing composition containing supermolecular tightening Dropsordry and a preparation method thereof, which comprises the following components in mass fraction: 10-14 parts of protein composition, 20-24 parts of chitosan modified Dropsordry, 5-7 parts of freeze-dried powder of Lactobacillus bulgaricus, 10-12 parts of hyaluronic acid, 6-8 parts of glycine and 15-17 parts of proline; each part of the protein composition comprises 20-30 parts of myosin, 30-34 parts of actin, 5-10 parts of hydrolyzed collagen and 240-280 parts of deionized water. The pelvic floor muscle repairing composition can reduce drug toxicity, reduce the amount of drug administration, continuously supplement the required elements of the body during treatment, and quickly relieve the constipation problem caused by the functional damage of the pelvic floor muscle.

The present invention relates to a pyridazinone derivative and a use thereof. Specifically, the present invention relates to a compound represented by general formula (I), a preparation method therefor, a pharmaceutical composition thereof, and a use of the compound represented by general formula (I) or the pharmaceutical composition thereof in the preparation, prevention and / or treatment of Myosin-mediated diseases, wherein each substituent in general formula (I) is as defined in the description.

The disclosure provides polynucleotides containing regions of the Myosin 15 (Myo15) promoter, as well as vectors containing the same, that can be used to promote expression of a transgene specifically in hair cells. The polynucleotides described herein may be operably linked to a transgene, such as a transgene encoding a therapeutic protein, so as to promote hair cell-specific expression of the transgene. The polynucleotides described herein may be operably linked to a therapeutic transgene and used for the treatment of subjects having or at risk of developing hearing loss or vestibular dysfunction.

The present application relates to a freshness indicator protein related to quality traits of low-temperature stored Siniperca chuatsi, endogenous proteases and applications. The freshness indicator endogenous proteases are related to postmortem proteolysis and meat softening of Siniperca chuatsi, including cathepsin B, cathepsin L and calpain. The freshness indicator proteins are related to quality changes occurring during postmortem cold storage of Siniperca chuatsi, including myoactin 1, myosin binding protein, LDB protein, actin-related protein, etc. The present application determines the change rule of endogenous protease activity of Siniperca chuatsi at different storage stages, and the dynamic influence on muscle proteolysis and muscle degradation of Siniperca chuatsi, and reveals the internal relationship with fish meat sensory quality and processing characteristics, and clearly defines the "critical point" of quality deterioration of Siniperca chuatsi. It provides clear guidance for the control of endogenous enzyme-mediated quality deterioration in the processing and storage process of Siniperca chuatsi.

Described herein are methods of treatment with myosin inhibitors based on protein levels; methods of monitoring response to treatment based on such protein levels; and methods of determining whether to treat a patient with a myosin inhibitor based on such protein levels. Such methods may include obtaining a biological sample of a subject, measuring one or more protein levels in the sample, analyzing the one or more protein levels, and determining the therapeutic response based on the analysis, and may also include treating the subject based on the determination of a therapeutic response.

The invention discloses the technical field of animal cell culture and cell culture meat, and provides a food-grade natural compound combination method for promoting efficient myogenic differentiation in vitro. According to the method disclosed by the invention, a combination of xanthophyll and arachidic acid is added into a basic myogenic differentiation induction culture medium to form a myogenic differentiation promoting culture medium. According to the myogenic differentiation culture medium system, the myogenic differentiation efficiency of the myogenic cells can be improved from about 23% to 45% or above, the myogenic fusion efficiency can be improved from about 18% to 33% or above, the problems that the in-vitro differentiation efficiency of the myogenic cells is low, the content of key proteins such as myosin is insufficient and the like are effectively solved, and the myogenic differentiation culture medium system is suitable for large-scale popularization and application. And a feasible scheme is provided for large-scale muscle fiber production of cell culture meat.

The invention is suitable for the technical field of cosmetic preparations, and provides a composite polypeptide composition and a preparation method thereof. The composition is prepared from the following raw materials in parts by weight: 20 to 40 parts of mussel mucin derived peptide, 10 to 20 parts of carnosine, 20 to 35 parts of polylysine-oligopeptide 1-lactitol-sodium citrate assembly, 30 to 50 parts of fermented centella asiatica extract, 10 to 30 parts of leontopodium alpinum stem cell extract, 100 to 200 parts of phospholipid, 30 to 60 parts of cholesterol and 100 to 150 parts of emollient. The preparation method comprises the following steps: dissolving fat-soluble and partial active components by using an organic phase, dispersing or dissolving water-soluble active components and an assembly by using a water phase, and carrying out rotary evaporation film formation, hydration and high-pressure homogenization to prepare the nano co-assembled lipid carrier. Through component synergy and a nano-carrier technology, the entrapment efficiency and stability of active components are remarkably improved, the skin permeability is enhanced, the synergistic effects of moisturizing, skin barrier repairing and aging resisting are achieved, and the composition is suitable for preparing various cosmetics.

The present invention relates to novel blood-brain barrier (BBB) ​​permeable substituted bicyclic derivatives capable of selectively inhibiting myosin light chain phosphate phosphorylation mediated by ROCK2 and / or Rho kinase, compositions comprising such derivatives, methods for preparing such derivatives and / or compositions, and methods for using such derivatives and / or compositions.

The invention relates to the technical field of microorganisms, and particularly discloses a bifidobacterium breve BB18 and an application of an exopolysaccharide BB18-EPS (extracellular polysaccharide) produced by the bifidobacterium breve BB18. The strain is preserved in the China General Microbiological Culture Collection Center on June 9, 2025, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.34621. The exopolysaccharide BB18-EPS secreted by the strain can be used as a food additive for gel modification of shrimp myofibrillar protein (MP), and the product performance is remarkably improved. Experiments prove that BB18-EPS drives ordered crosslinking of myosin through a hydrophobic effect, promotes transformation of a secondary structure of MP to alpha-helix, and optimizes the recombination efficiency of a molecular chain; meanwhile, through interaction of hydroxyl, sugar residues and water molecules, the density of a gel network is enhanced, and the thermal stability and the deformation resistance are improved. The composite gel system can be applied to the fields of minced penaeus vannamei products and the like, and the product texture and the processing yield are effectively improved.

The present disclosure relates to the use of split inteins for expressing Myosin-VIIa protein encoded by MYO7A gene in a subject in need thereof for gene therapy in particular for the treatment of MYO7A associated disease, preferably Usher syndrome type 1B.

This invention pertains to the pharmaceutical field and relates to a class of substituted indene compounds and their uses. Specifically, this invention relates to compounds of formula (I), or stereoisomers, tautomers, nitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts, or prodrugs of compounds of formula (I). The compounds and pharmaceutical compositions thereof involved in this invention, as myosin inhibitors, can be used to prepare medicaments for the prevention or treatment of myosin-related diseases, and particularly for the treatment of hypertrophic cardiomyopathy.

The application discloses a benzisothiazole carboxamide compound and application thereof. The benzisothiazole carboxamide compound has the characteristics of high specificity and high activity as an inhibitor of myosin motor domain, and can significantly inhibit the growth and development process and pathogenicity of pathogenic fungi, especially Pyricularia oryzae.

The invention discloses an application of a haplotype of a megalobrama amblycephala body weight associated SNP site in breeding, and belongs to the technical field of aquatic breeding. The haplotype is randomly formed by a haplotype I, a haplotype II and a haplotype III, basic groups at positions 457 and 770 of a myosin IB gene of the haplotype I are A and G respectively, basic groups at positions 457 and 770 of the myosin IB gene of the haplotype II are A and C respectively, basic groups at positions 457 and 770 of the myosin IB gene of the haplotype III are T, C, T and C respectively, and basic groups at positions 770 and 770 of the myosin IB gene of the haplotype III are A and G respectively. Compared with other diplotypes, the homozygous double V type randomly formed by the haplotype III has remarkable advantages in average weight and myosin IB gene expression, and can be used for auxiliary breeding of megalobrama amblycephala fast-growing new line molecules.

The invention relates to the technical field of food freezing, in particular to a food antifreeze agent and a preparation method and application thereof. The food antifreeze agent comprises carboxymethyl chitosan (CMCh) and basic amino acid. The food antifreeze agent is a binary compound system designed according to the'head and tail 'structural characteristics of myosin, a complementary synergistic mechanism of'head targeting enhancement + tail precise regulation' is formed, the food antifreeze agent has a very good antifreeze effect, and effective antifreeze can be achieved by only 0.5% (by weight) of the antifreeze agent.

To provide a new therapy targeting hair cells for the treatment of sensorineural hearing loss or vestibular dysfunction.SOLUTION: The present disclose provides polynucleotides containing a region of the myosin 15 (Myo15) promoter, as well as vectors containing the same, which can be used to promote expression of a transgene specifically in hair cells. The polynucleotides described herein can be operably linked to a transgene, such as a transgene encoding a therapeutic protein, to facilitate hair cell-specific expression of the transgene. The polynucleotides described herein can be operably linked to a therapeutic transgene and used in the treatment of a subject having or at risk of developing hearing loss or vestibular dysfunction.SELECTED DRAWING: Figure 1

The present invention is a method to improve physical-sports performance, reduce fatigue, combat physical-sports aging, and to cure and prevent physical injuries, based on an effective dose of glycine, L-proline, L-lysine, L-aspartic acid (or L-aspartate, citric acid, or citrate), and vitamin C. The method is based on the limitations and subsequent conditions of the metabolism in three aspects: (1) the synthesis of ATP in mitochondria, dependent on the Krebs cycle; (2) the synthesis of proteins of the passive mechanical system (collagen and elastin); (3) the mechanism of muscle contraction in actin-myosin interaction cross-bridge cycles. while ensuring that the diet must contain a sufficient amount of protein.

The invention discloses a compound shown as a formula (I), or a stereoisomer, a pharmaceutically acceptable salt and a pharmaceutical composition of the compound and the stereoisomer and the pharmaceutically acceptable salt, and application of the compound and the stereoisomer and the pharmaceutically acceptable salt in preparation of drugs for treating / preventing Myosin II mediated diseases, and all groups in the formula (I) are defined as in the specification.

The present invention relates to novel blood brain barrier (BBB) permeable substituted bicyclic derivatives that can selectively inhibit the phosphorylation of ROCK2 and / or Rho kinase mediated myosin light chain phosphate, compositions comprising the derivatives, methods for making the derivatives and / or compositions, and methods of using the derivatives and / or compositions.

A method is provided for diagnosing or prognosing a muscular dystrophy or a dystrophinopathy in a subject, the method comprising detecting the presence of a biomarker or a combination of biomarkers or detecting a change in level of a biomarker or a combination of biomarkers in a biological sample from the subject, wherein the biomarker is myomesin-3 (MYOM3), glycogen phosphorylase, muscle form (PYGM), titin (TTN), or filamin-C (FLNC), and the combination is a combination of any two or more of MYOM3, PYGM, TTN, or FLNC. In some aspects, the muscular dystrophy is Becker muscular dystrophy or Duchenne muscular dystrophy. A method is provided for diagnosing Duchenne muscular dystrophy in a subject, the method comprising detecting the presence of a biomarker or a combination of biomarkers or detecting a change in level of a biomarker or a combination of biomarkers in a biological sample from the subject, wherein the biomarker is myomesin-3 (MYOM3), glycogen phosphorylase, muscle form (PYGM), titin (TTN), filamin-C (FLNC), or myosin-2 (MYH2), and the combination is a combination of any two or more of MYOM3, PYGM, TTN, FLNC, or MYH2. Methods for monitoring disease progression by measuring levels of one or more biomarkers over course of the disease, and methods for determining the efficacy of a therapeutic treatment for the muscular dystrophy in a subject by measuring levels of one or more biomarkers before and / or after treatment also are provided.

Methods of administering a myosin inhibitor to a patient and related methods of risk mitigation including controls on distribution are described herein. Methods disclosed herein provide for safe administration of mavacamten and other myosin inhibitors, and mitigate the risk of heart failure due to systolic dysfunction.

The invention discloses an application of FGF12 (Fibroblast Growth Factor 12) in a medicine for improving intrauterine adhesion. A 95% ethanol-induced intrauterine adhesion rat model is constructed, and an adeno-associated virus carrying an FGF12 gene is injected into a uterine cavity for intervention, which indicates that the FGF12 can significantly activate a Rho / ROCK signal channel, further promotes phosphorylation of myosin light chain subunits on myosin light chain phosphatase, inhibits dephosphorylation of MLC, and improves the phosphorylation level of MLC in fibroblasts. The endometrial fibrosis process is inhibited, collagen deposition is remarkably reduced, the endometrial thickness and the gland number are recovered, and the TGF-beta1 expression level is improved. Meanwhile, the pregnancy rate is obviously increased, and the limitation of traditional treatment is broken through.

The invention discloses identification of nucleotide point mutation of a gene FfMyosin-5 related to fusarium moniliforme myosin 5 and application of the gene FfMyosin-5 in monitoring of resistance of a bactericide JS399-19, and particularly discloses a molecular detection method for identifying drug resistance of 422-site or 218-site amino acid mutation of the fusarium moniliforme FfMyosin-5 gene to JS399-19 and a special primer of the molecular detection method. The molecular detection method provided by the invention is high in sensitivity, good in stability and short in detection period, and can be used for monitoring the resistance gene frequency and the resistance generation and development condition of the field rice fusarium moniliforme to the bactericide JS399-19 in a high-throughput manner.

1. The name of the design product: packaging box (recombinant mussel myosin repair dressing). 2. The use of the design product: for the packaging of medicines. 3. The design points of the design product: the combination of patterns and colors. 4. The picture or photo that best shows the design points: perspective view. 5. The design for which protection is sought contains colors.

The invention relates to a construction method of mineral-induced non-denatured protein hydrogel, and belongs to the technical field of biological materials. According to the method, myofibril ternary mixed protein (para-myosin-tropomyosin-actin) extracted from aquatic products is taken as a raw material, and hydrogel with a three-dimensional network structure is formed under the co-driving of interaction between protein molecules and metal coordination crosslinking through induction of mineral metal ions such as Ca < 2 + >, Zn < 2 + > and Cu < 2 + >. The whole preparation process is mild in condition, and the natural structure and biological activity of protein can be maintained. The obtained hydrogel has good mechanical performance, biocompatibility and reversible regulation and control performance, and can be widely applied to the fields of wound repair, tissue engineering scaffolds, active substance delivery, edible embedding carriers and the like. The protein raw materials are wide in source, the preparation process is simple and efficient, and a new way is provided for development of novel protein-based biological materials.

Disclosed herein, in some aspects, are systems and methods for treating hypertrophic cardiomyopathy (HCM) in a subject. In some embodiments, the systems and methods described herein comprise monitoring a cardiac performance and optionally detecting an abnormality of said cardiac performance, in some cases after an initial HCM treatment is administered. In some cases, the initial HCM treatment includes administration of a myosin inhibitor, and / or septal myectomy. In some embodiments, said cardiac performance correlates with a right ventricular function and / or a pulmonary arterial pressure. In some embodiments, systems and methods described herein comprise identifying a therapy for a subject so as to help reduce the risk of de-performance teriorating a cardiac performance. In some cases, identifying the therapy includes predicting an effectiveness of a therapy with respect to a cardiac performance. In some embodiments, a recommendation is provided for adjusting a therapy based on an observed effect on a cardiac performance.

The invention relates to application of a cytoskeleton regulator in preparation of a blood coagulation promoting drug, and belongs to the technical field of biological medicines, and the blood coagulation promoting drug is a drug for treating or preventing hemorrhagic diseases related to low blood coagulation function. The hemorrhagic diseases comprise traumatic hemorrhage, surgical operation related hemorrhage, hepatopathy related hemorrhage, postpartum hemorrhage, hemophilia, hemorrhage caused by excessive anticoagulant drugs, thrombocytopenia or dysfunction related hemorrhage; the cytoskeleton regulator is one or more of a compound for inhibiting polymerization of actin microfilaments, a compound for inhibiting shrinkage of myosin and a ROCK kinase inhibitor; the cytoskeleton regulator can be used for preparing a procoagulant treatment drug, the effect is played by inducing endogenous cells of a body to release procoagulant particles, a brand new strategy is provided for a clinical hemostatic drug, and the cytoskeleton regulator can remarkably shorten the coagulation time of whole blood; the bleeding time can be remarkably shortened, the total blood loss amount is reduced, and the powerful in-vivo bleeding stopping effect is achieved.

The present invention discloses a pyridazinone cyclic compound represented by formula (I), its stereoisomer, deuterated product, solvate, pharmaceutically acceptable salt or cocrystal, and pharmaceutical compositions containing them, as well as their use in the manufacture of drugs for treating / preventing myosin II-mediated diseases, wherein each group in formula (I) is as defined in the specification. [C1] TIFF2026501712000288.tif36156

The present invention relates to novel substituted bicyclic derivatives that can selectively inhibit the phosphorylation of ROCK2 and / or Rho kinase mediated myosin light chain phosphate, compositions comprising the derivatives, methods for making the derivatives and / or compositions, and methods of using the derivatives and / or compositions.